Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
Sponsor: Memorial Sloan Kettering Cancer Center
Summary
This study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by CAR-T cell therapy.
Official title: A Phase II Study of IL-1 Receptor Antagonist Anakinra to Prevent Severe Neurotoxicity and Cytokine Release Syndrome in Patients Receiving CD19-Specific Chimeric Antigen Receptor (CAR) T Cells
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
62
Start Date
2019-10-30
Completion Date
2026-10
Last Updated
2025-11-05
Healthy Volunteers
No
Interventions
Anakinra
100mg subcutaneous
Locations (2)
Hackensack Meridian Health (Data collection only)
Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States